Browsing Category
Pharma Industry News
4747 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Theravance Biopharma cashes out remaining Trelegy royalties in $225m deal with GSK
Theravance Biopharma sells Trelegy royalties to GSK for $225M, unlocking shareholder value and reinforcing its focus on YUPELRI and ampreloxetine.
ATOMIC trial breakthrough: Atezolizumab + FOLFOX cuts colon cancer recurrence risk by 50%
Atezolizumab plus FOLFOX slashes recurrence risk in stage III dMMR colon cancer, says ATOMIC trial at ASCO 2025. Is this the new standard of care?
AstraZeneca Pharma India FY25 revenue jumps 32% to Rs 1,716cr on strong oncology growth
AstraZeneca Pharma India reports ₹1,716 Cr in FY25 revenue with 32% growth. Explore stock impact, new drug launches, and what’s next for pharma investors.
Avistone Biotechnology presents positive ASCO 2025 results for dual inhibitor therapy in EGFR-mutated NSCLC
Avistone reveals 50% ORR and 9.9-month PFS for its Vebreltinib–Andamertinib combo in MET-amplified NSCLC at ASCO 2025. Find out what this means for lung cancer care.
Zai Lab and Novocure’s TTFields therapy shows survival benefit in pancreatic cancer: PANOVA-3 results unveiled at ASCO 2025
Zai Lab and Novocure report TTFields improves survival in pancreatic cancer. Read how ASCO 2025 results could reshape the standard of care.
SMS Pharmaceuticals FY25 results: PAT up 39%, Rs 250cr capex planned for FY26 growth
SMS Pharmaceuticals posts 39% PAT growth, backed by integration gains and â‚ą250 Cr expansion. Will margin boosts and product diversification drive FY26 re-rating?
HER3-DXd shows promise in treating brain metastases: Inside the TUXEDO-3 trial results from ASCO 2025
HER3-DXd from Daiichi Sankyo and Merck shows intracranial activity in CNS cancers, as TUXEDO-3 results presented at ASCO 2025 spark major oncology interest.
The race for non-opioid pain relief: who’s leading the post-opioid era?
Explore the top companies and mechanisms leading the post-opioid pain relief revolution in 2025. Who's winning the race for safe, effective chronic pain drugs?
CirCode Biomed’s HM2002 gets FDA green light: World’s first circular RNA drug to enter U.S. clinical trials for heart disease
CirCode’s HM2002 becomes the first circular RNA drug cleared by the FDA for clinical trials in ischemic heart disease—setting a precedent in RNA therapeutics.
Why Iovance Biotherapeutics faces a class action lawsuit after a 45% stock crash
Iovance faces a class action lawsuit after cutting 2025 revenue guidance by 40%. Learn what triggered the stock’s 45% drop and how investors can file claims.